Abstract

Adenosine suppresses immune responses through the adenosine A2A receptors (A2AR). We evaluated the expression of A2AR in blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer's disease (AD), and controls in order to verify if it may help distinguish different forms of cognitive decline. There was a significant linear increase in both mRNA levels and receptor density from multiple cognitive domain MCI (mcd-MCI) to amnestic MCI (a-MCI), spanning through AD and controls, without any significant difference between the latter two groups of subjects. These data, which need to be confirmed in a larger number of patients, suggest that expression of A2AR in PBMCs may be a valuable means of differentiating a-MCI and mcd-MCI.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call